

Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24

Camelia Savulescu^{1,2}, Albert Prats-Urbe^{1,2}, Kim Brolin³, Anneli Uusküla⁴, Colm Bergin⁵, Catherine Fleming⁶, Rita Murri^{7,8}, Viesturs Zvirbulis⁹, Dace Zavadska¹⁰, Vania Gaio¹¹, Corneliu P Popescu^{12,13}, Raluca Hrisca¹⁴, Maria Cisneros^{15,16}, Miriam Latorre-Millán¹⁷, Liis Lohur¹⁸, Jonathan McGrath⁵, Lauren Ferguson⁶, Katleen De Gaetano Donati^{7,8}, Ilze Abolina⁹, Dagne Gravelle¹⁰, Ausenda Machado¹¹, Simin-Aysel Florescu^{12,13}, Mihaela Lazar¹⁹, Pilar Subirats²⁰, Laura Clusa Cuesta¹⁷, Jacklyn Sui⁵, Claire Kenny⁶, Rosaria Santangelo^{7,8}, Dainis Krievins⁹, Elza Anna Barzdina¹⁰, Camila Valadas Henriques²¹, Alma Gabriela Kosa¹², Saftica-Mariana Pohrib¹⁴, Carmen Muñoz-Almagro^{15,16,22}, Ana Milagro¹⁷, Sabrina Bacci³, Anthony Nardone¹, VEBIS HCW VE study group²³

1. Epiconcept, Paris, France
2. These authors contributed equally to this work and share first authorship. The other co-authors are listed in the alphabetical order of their countries.
3. European Centre for Disease Prevention and Control, Stockholm, Sweden
4. University of Tartu, Institute of Family Medicine and Public Health, Tartu, Estonia
5. Saint James's Hospital, Dublin, Ireland
6. Galway University Hospital, Galway, Ireland
7. Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
8. Università Cattolica del Sacro Cuore, Rome, Italy
9. Pauls Stradins Clinical University Hospital, Riga, Latvia
10. Children Clinical University Hospital, Riga, Latvia
11. Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
12. Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania
13. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
14. Central Military Emergency University Hospital "Dr. Carol Davila", Bucharest, Romania
15. Institut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain
16. Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain
17. Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS Aragon, Zaragoza, Spain
18. Viljandi Hospital, Viljandi, Estonia
19. Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania
20. Department of Occupational Risk Prevention, Hospital Sant Joan de Deu, Barcelona, Spain
21. Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
22. Ciber of Epidemiology and Public Health CIBERESP, Madrid, Spain
23. The additional collaborators of the VEBIS HCW VE study group are listed at the end of the article.

Correspondence: Camelia Savulescu (c.savulescu@epiconcept.fr)

Collaborators: The collaborators are listed at the end of the article.

Citation style for this article:

Savulescu Camelia, Prats-Urbe Albert, Brolin Kim, Uusküla Anneli, Bergin Colm, Fleming Catherine, Murri Rita, Zvirbulis Viesturs, Zavadska Dace, Gaio Vania, Popescu Corneliu P, Hrisca Raluca, Cisneros Maria, Latorre-Millán Miriam, Lohur Liis, McGrath Jonathan, Ferguson Lauren, De Gaetano Donati Katleen, Abolina Ilze, Gravelle Dagne, Machado Ausenda, Florescu Simin-Aysel, Lazar Mihaela, Subirats Pilar, Clusa Cuesta Laura, Sui Jacklyn, Kenny Claire, Santangelo Rosaria, Krievins Dainis, Barzdina Elza Anna, Valadas Henriques Camila, Kosa Alma Gabriela, Pohrib Saftica-Mariana, Muñoz-Almagro Carmen, Milagro Ana, Bacci Sabrina, Nardone Anthony, VEBIS HCW VE study group. Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24. *Euro Surveill.* 2024;29(44):pii=2400680. <https://doi.org/10.2807/1560-7917.ES.2024.29.44.2400680>


Article received on 14 Oct 2024 / Accepted on 31 Oct 2024 / Published on 31 Oct 2024

COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: -17 to 48), 49% (95% CI: -8 to 76) before and -11% (95% CI: -84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.

COVID-19 vaccination recommendations prioritise healthcare workers (HCWs), considering their exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) and their key role in the functioning of healthcare systems. In the European Union/European Economic Area (EU/EEA), HCWs were considered a priority for COVID-19 revaccination during the autumn 2023 campaign [1], and the World Health Organization (WHO) recommended revaccination of HCWs 12 months after their last dose [2]. Because the Omicron sub-lineage XBB.1.5 predominated in spring 2023, the COVID-19 vaccines were adapted to target this emerging strain, and the first XBB.1.5 vaccine was authorised for use in the EU/EEA in August 2023. Omicron BA.2.86/JN.1 emerged in

FIGURE 1

Inclusion and exclusion criteria, VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, seven European countries, season 2023/24 (n = 1,483)



HCW: healthcare worker.

^a HCWs could contribute to both vaccinated and unvaccinated groups.

the EU/EEA at the end of 2023, according to data available on the European Respiratory Virus Surveillance Summary (ERVISS) [3]. Evidence for COVID-19 vaccine recommendation in the HCW population remains scarce. Within the Vaccine Effectiveness, Burden and Impact (VEBIS) project, we aimed to measure the COVID-19 vaccine effectiveness (CVE) in HCWs, in the winter season 2023/24.

VEBIS healthcare worker cohort

In this prospective cohort study [4], we recruited HCWs from 13 hospitals in seven countries (Estonia, Ireland, Italy, Latvia, Portugal, Romania, and Spain). At a weekly follow-up, HCWs provided nasopharyngeal or saliva

samples to detect incident SARS-CoV-2 infections and completed a questionnaire to update vaccination and exposure information. We excluded HCWs who did not provide informed consent, missed important information for analysis (e.g. vaccination status and laboratory results) or presented discordant serology and virology results.

Definition of exposures, outcomes, covariates

We defined current vaccination as HCWs who received a dose of any COVID-19 vaccine brand during the autumn 2023 campaign and unvaccinated as HCWs who did not receive a vaccine dose during this campaign,

regardless of the number of doses and timing of previous vaccination(s). We stratified previous vaccination in (i) more than 365 days or unvaccinated before the autumn 2023 vaccination campaign and (ii) 90–365 days before the autumn 2023 campaign. We grouped the time since current vaccination in 7–59, 60–119 and ≥ 120 days.

The main outcome of the study was time to the first incident SARS-CoV-2 infection, detected by RT-PCR, regardless of symptoms. Secondary outcomes included symptomatic and asymptomatic COVID-19 in HCWs, depending on whether or not symptoms were reported from 14 days before to 7 days after the first positive test.

Recent previous SARS-CoV-2 infection was defined as self-reported SARS-CoV-2 infection after 1 November 2022 (the month with the start of predominant circulation of Omicron XBB sub-lineage in the participating countries). Non-recent previous infection was defined as self-reported previous SARS-CoV-2 infection before 1 November 2022. We excluded from all analyses a period of 60 days after a positive RT-PCR sample [5].

Vaccine effectiveness analysis

First, we measured the CVE of the autumn 2023 vaccine dose, comparing the current vaccinated with unvaccinated HCWs. In secondary analyses, we measured the CVE by time since previous vaccination, by time since current vaccination, by recent previous infection overall, and by symptomatic status of the SARS-CoV-2 infection, stratified before and after the start of predominant circulation of the Omicron BA.2.86/JN.1 virus sub-lineage. Using Cox regression, we calculated effectiveness as:

$$\text{CVE} = (1 - \text{hazard ratio of current vaccination}) \times 100.$$

We adjusted the CVE for hospital, age, sex, at least one underlying condition, and recent SARS-CoV-2 infection.

Descriptive and vaccine effectiveness results

Between October 2023 and May 2024, out of 1,483 HCWs approached, 1,477 were enrolled, ranging from 160 in Italy to 304 in Romania. After applying the inclusion and exclusion criteria, 1,305 HCWs remained in the CVE analysis (Figure 1). Vaccinated HCWs were more likely to be older or to work as medical doctors, and less likely to be female or current smokers (Table 1).

We detected 244 SARS-CoV-2 infections (Figure 1): 37 among vaccinated (1.03 per 1,000 person-days of observation) and 207 among unvaccinated HCW (1.7 per 1,000 person-days). Of these infections, 128 (52%) were symptomatic. The cumulative incidence was lower among the vaccinated throughout the entire follow-up regardless of the outcome used (Figure 2).

The adjusted CVE against SARS-CoV-2 infection was 22% (95% confidence interval (CI): –17 to 58) overall,

with a CVE point estimate of 26% against asymptomatic and 17% against symptomatic infection, with overlapping confidence intervals. The CVE point estimates were 33% in HCWs with no recent prior infection and 23% in HCWs with a previous vaccination >365 days. The CVE was 49% (95% CI: –8 to 76) before the start of BA.2.86/JN.1 circulation and below 0 during the BA.2.86/JN.1 circulation, with higher CVE point estimates 7–59 days after vaccination. The CVE point estimates were below 0 in HCWs with recent prior infection and vaccinated 90–365 days before the autumn dose, as well as ≥ 120 days after vaccination (Table 2).

Discussion

We estimated the effectiveness of an autumn 2023 COVID-19 vaccine dose in HCWs from 13 European hospitals of the VEBIS HCW prospective cohort study. The results suggest a moderate-to-low CVE among HCWs against SARS-CoV-2 infection overall. However, the CVE point estimates suggest a higher protection of COVID-19 vaccines against XBB.1.5 sub-lineages, in circulation before the start of predominant circulation of Omicron BA.2.86/JN.1. The CVE point estimates were higher in HCWs with non-recent previous SARS-CoV-2 infection, suggesting higher benefit of vaccination in these HCWs. The CVE point estimates were also higher for recent vaccination (<60 days), even during predominant circulation of BA.2.86/JN.1 when CVE became lower than 0 after 60 days. The null CVE and wide confidence intervals in those with a recent prior vaccination suggest that, in the described scenario, vaccination more frequently than annually may not provide additional protection against SARS-CoV-2 infection overall.

Our results were similar to those of a study conducted in the United States in HCWs with similar vaccination coverage before (CVE = 42%) and during JN.1 circulation (CVE = 19%) [6]. They were also similar to the overall estimates by time since vaccination during a 6-month season 2023/24 and to the estimates in HCWs with no recent previous infection in a study from the United Kingdom with higher vaccination coverage [7].

Disentangling the effect of time since last vaccination from the effect of virus evolution was of particular importance for CVE studies during the 2023/24 season [8,9]. As the protection remains at moderate level for about 4 months after vaccination and SARS-CoV-2 variants and sub-lineages continuously emerge, efforts need to be made to better predict the immune evasion [10] and take into account the antigenic distance in CVE estimation [11]. Meanwhile it remains necessary, in addition to vaccination, to recommend frequent testing for HCWs in contact with suspected cases in hospital and in the community, and to regularly reinforce the use of protective equipment when in contact with vulnerable patients, especially when new virus strains emerge.

One of the main strengths of our study was the frequent testing regardless of symptoms, which captured


TABLE 1

Main characteristics of participants at enrolment by vaccination status, VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, seven European countries, season 2023/24 (n = 1,305)

Characteristic	Vaccinated in season 2023/24 (n=300)		Not vaccinated in season 2023/24 (n=1,005)	
	n	%	n	%
Sex				
Female	235	78.3	849	84.5
Male	65	21.7	156	15.5
Age group (years)				
18–34	40	13.3	224	22.3
35–39	33	11.0	111	11.1
40–44	47	15.7	143	14.2
45–49	52	17.3	177	17.6
50–54	42	14.0	154	15.3
≥ 55	86	28.7	196	19.5
Role				
Medical doctor	53	17.7	161	16.0
Nurse	74	24.7	491	48.9
Administration/reception	48	16.0	134	13.3
Ancillary	8	2.7	40	4.0
Allied	10	3.3	23	2.3
Laboratory	13	4.3	47	4.7
Other	38	12.7	98	9.8
Missing	56	18.7	11	1.1
Smoking				
Never smoked	170	56.7	509	50.6
Ex-smoker	70	23.3	255	25.4
Current smoker	32	10.7	234	23.3
Missing	28	9.3	7	0.7
Underlying conditions				
At least one	78	26.0	278	27.7
No underlying condition	212	70.7	698	69.4
Missing	10	3.3	29	2.9
Recent previous COVID-19 episode				
Yes	72	24.0	324	32.2
No	184	61.3	653	65.0
Missing	44	14.7	28	2.8
Time since last previous COVID-19 episode				
Median time in days (range)	521 (60–1371)		493 (60–1,481)	
Brand autumn vaccination dose				
Not XBB1.5-adapted	55	18.3	Not applicable	
XBB1.5-adapted	245	81.6		
Time since last vaccination dose				
Median time since previous dose in days (range)	895 (224–1,122)		741 (132–1,107)	
Number of vaccine doses ever received before the autumn 2023 vaccination campaign				
Unvaccinated	0	0.0	58	5.8
1 dose	2	0.7	44	4.4
2 doses	7	2.3	216	21.5
3 doses	38	12.7	502	49.9
4 doses	134	44.7	183	18.2
5 doses	119	39.7	2	0.2

FIGURE 2

Kaplan-Meier plots of time (days) from enrolment to SARS-CoV-2 infection in VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, by vaccination status, seven European countries, season 2023/24 (n = 1,305)



asymptomatic and milder infections; this is important in studies on emerging variants/sub-lineages and in the HCW population. Another strength was the thorough collection of vaccination and previous SARS-CoV-2 infection status.

The main limitation of the study was its low precision of CVE estimates, due to low uptake of the vaccine at the participating hospitals and to the limited number of events, resulting in small sample size particularly when further adjusting by other confounders such as the number of previous vaccine doses or professional role. Adding these covariates in the regression model increased the overall CVE point estimate by 8%, but with a poorer fit of the data than the reported model and with concerns around correlation with existing covariates in the model. Secondly, vaccinated participants seemed to be more likely to accept further vaccination: 45% had four doses compared with 18% in those unvaccinated during the 2023 vaccination campaign, potentially overestimating the CVE results (which was not the case when adjusting by number of previous vaccination doses, as described above). Finally, the studied season was characterised by an initial circulation of Omicron XBB.1.5, later replaced by sub-lineage BA.2.86 and its offspring JN.1. As eight hospitals lacked sequencing information to more accurately define the periods with predominant circulation of the Omicron

sub-lineages, we used ERVISS data reported at country level as a proxy; further investigation is needed to check the consistency of our approach.

Conclusion

Our results indicate that an autumn 2023 COVID-19 vaccine dose presented a moderate-to-low reduction of 22% in the risk of SARS-CoV-2 infection in HCWs overall. Nevertheless, the vaccine protected almost one in two HCWs in the period before the predominant circulation of BA.2.86/JN.1 sub-lineage and during less than 60 days after vaccination. Timely deployment of vaccines is crucial for the COVID-19 vaccination programme. With increased sample size, our VEBIS HCW cohort study can provide more precise information to inform key vaccination policies and public health interventions for HCWs in the following seasons.

TABLE 2

Adjusted vaccine effectiveness in the primary and secondary analyses, VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, seven European countries, season 2023/24 (n = 1,305)

Analysis	Vaccinated			Unvaccinated			Adjusted ^a CVE
	Number HCWs	Events	Person-days	Number HCWs	Events	Person-days	
Overall effect							
SARS-CoV-2 infection	300	37	35,657	1,130	207	121,394	22 (-17 to 48)
Asymptomatic infection	300	15	35,657	1,130	101	121,394	26 (-43 to 61)
Symptomatic COVID-19	300	22	35,657	1,130	106	121,394	17 (-40 to 51)
By recent prior infection							
No recent prior infection	184	25	21,135	738	150	70,024	33 (-9 to 58)
Recent prior infection	92	8	9,848	486	53	48,601	-9 (-139 to 50)
Time since previous vaccination							
Vaccinated 90–365 days before the current season vaccination	300	37	35,657	165	10	5,186	-31 (-245 to 50)
Vaccinated >365 days before the current season vaccination	300	37	35,657	1,082	197	116,208	23 (-16 to 49)
Before/after BA.2.86 predominant circulation and time since vaccination in season							
Before	190	9	4,999	871	108	36,503	49 (-8 to 76)
7–59 days vs >365 days before	190	9	4,854	801	100	32,278	47 (-11 to 75)
≥ 60 days vs >365 days before	21	0	145	801	100	32,278	Not calculated
After	296	28	30,658	963	99	84,891	-11 (-84 to 34)
7–59 days vs >365 days before	231	9	5,849	958	97	83,930	16 (-88 to 63)
≥ 60 days vs >365 days before	283	19	24,809	958	97	83,930	-25 (-128 to 31)
Time since vaccination in season vs >365 days before							
7–59 days	267	18	10,703	1,082	197	116,208	24 (-29 to 55)
60–119 days	251	9	6,658	1,082	197	116,208	39 (-43 to 74)
120–149 days	243	9	16,080	1,082	197	116,208	-2 (-114 to 52)

CVE: COVID-19 vaccine effectiveness; HCW: healthcare worker; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a Adjusted by age sex, site, at least one underlying condition, recent previous SARS-CoV-2 infection (Participants with at least one covariate missing were not included in the adjusted model).

Collaborators in VEBIS HCW study group

Hanna Sepp, Lisa Domegan, Joan O'Donnell, Maeve Kernan, Anna Moriarty, Conor Moran, Giulia De Angelis, Silvia Lamonica, Giulia Menchinelli, Cinzia Recine, Silvia Zelli, Alice Tondinelli, Benedetta Falasca, Janis Meisters, Laura Zemite, Hilda Darta Snipe, Estere Ergle, Ana Palmira Amaral, João Almeida Santos, Daniela Dias, Licinia Gomes, Miguel Lança, Henrique Carvalho, Jose Alves, Daniel R. Codreanu, Alexandru Marin, Amaresh Pérez-Arguello, Iolanda Jordan, Juan Jose Garcia-Garcia, Antonio Rezusta, Alexander Tristancho, Ignacio Ezpeleta, Sandra Dueñas, Noelia Terren, Tamara Valero, Nieves Felisa Martínez, Yolanda Gracia, David Martínez, Beatriz Gilaberte, Cristina Carrasco, Carmen Martínez, Maria Pilar Rubio, Maria Gemma Martínez, Bruno del Moral, Ana Maria Sabio, Raquel Guiomar, Aryse Melo, Francisco Pozo, Ranya Mulchandani, Madelyn Rojas

Ethical statement

The planning, conduct and reporting of the current study was in line with the Declaration of Helsinki, as revised in 2013 (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects>). Informed consent was obtained from each participant at the enrolment in the study. The study was approved by the Ethical review committees from each hospital: Tartu Ülikooli inimüuringute eetika komitee, Estonia: 382/M-7; Clinical research ethics committee, Galway University Hospital, Ireland: C.A. 2693; SJH/TUH Joint Research

Ethics Committee, Ireland: 0513; Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Rome, Italy : 00372/23; Ethics Committee for Clinical Research at Pauls Stradins Clinical University Hospital, Latvia: 241023 - 3L; Ethics Committee for Clinical Research at Pauls Stradins Clinical University Hospital, extended to Children Clinical University Hospital, Latvia: 241023 - 10L; Comissão de Ética para a Saúde, INSA Doutor Ricardo Jorge, Portugal: INSA-IM60_05; Comisia de Etica a Spitalului Clinic de Boli Infectioase si Tropicale “Dr. Victor Babes”, Romania: 14420; Comisia Locala de Etica a Spitalului Universitar de Urgenta Militar Central “Carol Davila”, Romania: 646; Comité de Ética de la Investigación de la Comunidad Autónoma de Aragón (CEICA), HU Miguel Servet, Zaragoza, Spain: PI22/483; Comité De Ética De La Investigación Con Medicamentos, Sant Joan de Déu, Fundacio de Recerca, Barcelona, Spain: 17/2023.

Funding statement

This study was funded by European Centre for Disease Prevention and Control through “Vaccine Effectiveness, Burden and Impact Studies” (VEBIS) Lot 2 “Assessment of COVID-19 and influenza vaccine effectiveness among health-care workers” framework contract ECDC/2021/017.

Use of artificial intelligence tools

None declared.

Data availability

Data will be made available on request.

Acknowledgements

We thank all participants, hospital staff and study investigators not listed above for their efforts to conduct this study. We are also grateful to the following study team members:

Estonia: Kadri Kõivumägi, Natalia Nikitina, Anna Aleksandrova, Anastassia Kuželko.

Ireland: Irene Flynn Dowling; David Byrne; Noeleen Maher; Nicola Murphy.

Portugal: Ana Catarina Dias, Filipe Pimenta, Rui Pedro Lopes, Pedro Nunes, Filipa Chaves, Catarina Barradas.

Romania: Camelia Grancea, Oana Popescu, Catalina Pascu, Sorin Dinu, Alina Elena Ivanciuc, Iulia Bistriceanu, Mihaela Oprea, Maria Elena Mihai.

Spain: Lourdes Roc Alfaro, Sonia Usón Lucea, Beatriz Órpez Villen, Víctor Cantín-Lahoz, Emilia Ferrer López, María Pilar Martínez López, Miriam Infante Garza, Pilar Díaz Díaz, (HUMS, Zaragoza); Jesus Marquez, Ana Codina, Cristina Jou (Biobank- Hospital Sant Joan de Deu), Marta Cubells and Felipe Pérez-Soler (Clinical Research Unit-Institut de Recerca Sant Joan de Deu).

We also thank Esther Kissling and Baltazar Nunes for valuable comments on early draft of the manuscript, as well as to Valerie Nancey and Djenaba Bamba for their support in the study.

Conflict of interest

APU reported payment under EMA DARWIN EU project outside of the submitted work. MLM, AM, LC reported additional support received from ISIDORE (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. CPP, SAF reported speaker fees from and participation in Advisory board of Pfizer and MSD. SAF reports also participation in Advisory board of Gilead. CMA reported speaker fees from MSD, Pfizer and Sanofi. JS reported support for attending ESID conference 2022 from Takeda Pharmaceutical. RH and SP reported grant attributed to their institution on "PSCD Longitudinal evaluation of SARS CoV-2 immune status post-natural infection and post-vaccination. All other authors declare no conflicts of interest related to this work.

Authors' contributions

CS coordinated the VEBIS HCW VE network, wrote the study protocol, contributed to the data analysis and interpretation of the results and wrote the first draft of the manuscript. APU undertook the statistical analysis on which the research article is based, helped interpret results, and contributed to first draft of the manuscript. KB and SB were involved in the study design, interpretation of results, and the review of all versions of the manuscript. AN was involved in the original methodological design of the study (generic protocol), coordinated the VEBIS HCW VE network, helped interpret results, and contributed to all versions of the manuscript. AU, CB, CF, RM, VZ, DZ, VG, CPP, RH, MC, MLM, LL, JM, LF, KGD, IA,

DG, AM, SAF, ML, PS, LCC, JS, CK, RS, DK, EAB, CVH, AGK, SMP, CMA, AM and the VEBIS HCW VE study group, were responsible for the coordination of the study at the national/regional/hospital level, contributed to developing the study site-specific protocols, were in charge of the collection, management and validation of the clinical and laboratory data. They interpreted the results, reviewed and contributed to all versions of the manuscript. All authors approved the final version of the manuscript.

References

1. European Centre for Disease Prevention and Control (ECDC). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. Amsterdam: EMA; Stockholm: ECDC; 2023. Available from: <https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants>
2. World Health Organization (WHO). WHO roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity. Geneva: WHO; 2023. Available from: <https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2-eng.pdf?sequence=1>
3. European Centre for Disease Prevention and Control (ECDC). The European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 11 Jun 2024]. Available from: <https://www.ecdc.europa.eu/en/publications-data/european-respiratory-virus-surveillance-summary-erviss>
4. European Centre for Disease Prevention and Control (ECDC). Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 3.0. Stockholm: ECDC; 2024. Available from: <https://www.ecdc.europa.eu/en/publications-data/generic-protocol-ecdc-studies-covid-19-vaccine-effectiveness>
5. European Centre for Disease Prevention and Control (ECDC). Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. Stockholm: ECDC; 2021. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Reinfection-with-SARSCoV2-implementation-of-a-surveillance-case-definition.pdf>
6. Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Effectiveness of the 2023-2024 Formulation of the coronavirus disease 2019 messenger RNA vaccine. *Clin Infect Dis*. 2024;79(2):405-1.
7. Kirwan PD, Foulkes S, Munro K, Sparkes D, Singh J, Henry A, et al. Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024. *J Infect*. 2024;89(5):106293. <https://doi.org/10.1016/j.jinf.2024.106293> PMID: 39343245
8. Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early estimates of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. *MMWR Morb Mortal Wkly Rep*. 2024;73(4):77-83. <https://doi.org/10.15585/mmwr.mm7304a2> PMID: 38300853
9. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, et al. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. *Vaccine*. 2024;42(19):3931-7. <https://doi.org/10.1016/j.vaccine.2024.05.067> PMID: 38839521
10. Thadani NN, Gurev S, Notin P, Youssef N, Rollins NJ, Ritter D, et al. Learning from prepandemic data to forecast viral escape. *Nature*. 2023;622(7984):818-25. <https://doi.org/10.1038/s41586-023-06617-0> PMID: 37821700
11. Cao L, Lou J, Chan SY, Zheng H, Liu C, Zhao S, et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. *Nat Med*. 2022;28(8):1715-22. <https://doi.org/10.1038/s41591-022-01877-1> PMID: 35710987

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2024.